About
RDD Pharma is a specialty drugcompanydeveloping targeted pharmacological treatments for diseases of the anorectal region, such as anal fissures, fecal incontinence, and pruritus ani. A pharmaceutical compound targeting radiation proctitis is also in preclinical development. The company focuses on finding new uses for existing drugs. By choosing medications that are already approved for other indications and combining them with aproprietary drug-delivery technology, RDDbenefits from a short regulatory route while maintaining patent protection. RDD recently completed a successful phase-2a study of RDD 0315 in fecal incontinence, which reached the primary endpoint (lowered frequency of incontinence events). The company is also initiating a phase-3 study for treatment of chronic anal fissure with RDD 1219.